tiprankstipranks
IGC Pharma (DE:IGS1)
FRANKFURT:IGS1
Holding DE:IGS1?
Track your performance easily

IGC Pharma (IGS1) Income Statement

6 Followers

IGC Pharma Income Statement

Last quarter (Q2 2025), IGC Pharma's total revenue was $412.00K, an increase of 149.70% from the same quarter last year. In Q2, IGC Pharma's net income was $-1.72M. See IGC Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Mar 24Mar 23Mar 22Mar 21Mar 20
Total Revenue
$ 1.44M$ 1.34M$ 911.00K$ 397.00K$ 898.00K$ 4.07M
Cost of Revenue
$ 694.00K$ 612.00K$ 469.00K$ 203.00K$ 307.00K$ 3.96M
Gross Profit
$ 749.00K$ 733.00K$ 442.00K$ 194.00K$ 113.00K$ 115.00K
Operating Expense
$ 10.04M$ 10.56M$ 12.05M$ 15.62M$ 8.81M$ 6.98M
Operating Income
$ -9.29M$ -9.80M$ -11.57M$ -15.43M$ -8.72M$ -6.86M
Net Non Operating Interest Income Expense
$ -2.00K$ -5.00K$ -5.00K$ 5.00K$ 3.00K-
Other Income Expense
$ 2.47M$ 3.20M$ -65.00K$ 412.00K$ 87.00K$ 451.00K
Pretax Income
$ -11.76M$ -13.00M$ -11.51M$ -15.02M$ -8.81M$ -7.32M
Tax Provision
--$ -667.00K$ -385.00K$ -78.00K$ -3.08M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -11.76M$ -13.03M$ -11.54M$ -15.02M$ -8.78M$ -7.32M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 10.74M$ 11.17M$ 12.52M$ -15.82M$ 9.12M$ 6.98M
Net Income From Continuing And Discontinued Operation
$ -11.76M$ -13.00M$ -11.51M$ -15.02M$ -8.81M$ -7.32M
Normalized Income
$ -6.96M$ -6.12M----
Interest Expense
------
EBIT
$ -9.17M$ -12.99M$ -12.17M$ -15.40M$ -8.72M$ -7.32M
EBITDA
$ -8.54M$ -12.36M$ -11.52M$ -14.74M$ -8.25M$ -7.17M
Currency in USD

IGC Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis